Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update
Disc Medicine's pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria met all primary and secondary endpoints, reducing whole-blood metal-free PPIX by 41.4% versus placebo and adding 12.2 hours of monthly pain-free light exposure. The company plans to resubmit the bitopertin NDA by end of 2026, with an FDA decision anticipated by mid-2027, and will announce selcodebart pivotal plans in anemia of myelofibrosis after an end-of-Phase 2 FDA meeting. Disc ended Q3 with $682.8 million in cash and securities, and an October offering adding $485.9 million net proceeds extends the runway into 2030, funding the anticipated bitopertin launch.
Key figures
- Drug Name
- bitopertin
- Guidance
- Bitopertin NDA resubmission by end of 2026; FDA decision anticipated by mid-2027; end-of-Phase 2 FDA meeting feedback on selcodebart in anemia of MF by year-end
- Phase Of Trial
- Phase 3
- Cash runway
- into 2030
- Net loss q3
- 59500000
- Cash position
- 682800000
- Rnd expense q3
- 44100000
- Sga expense q3
- 20100000
- Pix reduction vs placebo
- 41.4%
- Light tolerance gain hours
- 12.2
- October offering net proceeds
- 485900000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.